TWSTMEDIUM SIGNALFINANCIAL10-K

TWST showed meaningful improvement in operating performance with substantially reduced losses across key metrics, though cash position declined and receivables grew notably.

The company demonstrated significant progress in loss reduction with operating income improving by over one-third and net losses meaningfully narrowing, suggesting better operational efficiency or cost management. However, the substantial growth in accounts receivable paired with declining cash reserves warrants monitoring for potential collection or working capital management issues.

Comparing 2025-11-17 vs 2024-11-18View on EDGAR →
FINANCIAL ANALYSIS

TWST's financial position showed mixed signals with meaningful improvements in profitability metrics - operating income losses narrowed substantially and net losses were significantly reduced year-over-year. The balance sheet revealed growing business activity through notably higher accounts receivable and increased inventory levels, while debt declined meaningfully. However, the company's cash position weakened with a 19% decline in cash equivalents, and total liabilities increased, creating a working capital dynamic that requires careful monitoring despite the improved operational performance.

FINANCIAL STATEMENT CHANGES
Interest Expense
P&L
-93.7%
$80K→$5K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

Accounts Receivable
Balance Sheet
+63.4%
$34.9M→$57.0M

Receivables surged 63.4% — revenue recognized but not yet collected; watch for collection issues or channel stuffing.

Net Income
P&L
+62.8%
-$208.7M→-$77.7M

Net income grew 62.8% — bottom-line growth signals improving overall business health.

Total Debt
Balance Sheet
-44.5%
$7.5M→$4.2M

Debt reduced 44.5% — deleveraging strengthens balance sheet and reduces financial risk.

Operating Income
P&L
+38.3%
-$220.8M→-$136.3M

Operating leverage kicking in — revenue growth outpacing cost growth, a hallmark of scaling businesses.

Current Liabilities
Balance Sheet
+28.7%
$71.0M→$91.4M

Current liabilities rose 28.7% — increased short-term obligations, watch current ratio.

Operating Cash Flow
Cash Flow
+25.7%
-$64.1M→-$47.6M

Operating cash flow grew 25.7% — strong conversion of earnings to cash, healthy business fundamentals.

Total Liabilities
Balance Sheet
+19.3%
$141.6M→$168.9M

Liabilities increased 19.3% — monitor debt-to-equity ratio and interest coverage.

Cash & Equivalents
Balance Sheet
-19.1%
$226.3M→$183.0M

Cash decreased 19.1% — monitor burn rate and upcoming capital needs.

Inventory
Balance Sheet
+17.6%
$24.1M→$28.3M

Inventory built 17.6% — monitor whether demand supports this build or if write-downs may follow.

LANGUAGE CHANGES
NEW — 2025-11-17
PRIOR — 2024-11-18
ADDED
Market for R egistrant s C ommon E quity, R elated S tockholder M atters and I ssuer P urchases of E quity S ecurities 45 Item 6.
Management s D iscussion and A nalysis of F inancial C ondition and R esults of O perations 47 Item 7A.
Changes in and D isagreements w ith A ccountants on A ccounting and F inancial D isclosure 95 Item 9A.
Security O wnership of C ertain B eneficial O wners and M anagement and R elated S tockholder M atters 98 Item 13.
Readers are urged to carefully review and consider all of the information in this Form 10-K and in other documents we file from time to time with the Securities and Exchange Commission (the "SEC").
In fields such as health care, food/agriculture, industrial chemicals/materials and academic research, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet.
We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
Building from this platform, we deliver products and services for a wide range of uses and markets.
We have applied our unique technology to manufacture a broad range of products, including synthetic genes, tools for next generation sequencing ("NGS"), sample preparation, and both products and services for drug discovery and development, all designed to enable our customers to conduct research more efficiently and effectively.
We sell our products and services to a global customer base of more than 3,800, customers across a broad range of industries.
REMOVED
Market for registrant s common equity, related stockholder matters and issuer purchases of equity securities 44 Item 6.
Management s discussion and analysis of financial condition and results of operations 47 Item 7A.
Changes in and disagreements with accountants on accounting and financial disclosure 93 Item 9A.
Security ownership of certain beneficial owners and management and related stockholder matters 96 Item 13.
Readers are urged to carefully review and consider all of the information in this Form 10-K and in other documents we file from time to time with the Securities and Exchange Commission, or SEC.
In fields such as health care, food/agriculture, industrial chemicals/materials, academic research and data storage, by using our products, our customers are developing ways to better lives and improve the sustainability of the planet.
We have developed a disruptive DNA synthesis platform to industrialize the engineering of biology that provides DNA for a wide range of uses and markets.
We have applied our unique technology to manufacture a broad range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing, or NGS, sample preparation, and antibody libraries for drug discovery and development, all designed to enable our customers to conduct research more efficiently and effectively.
Leveraging our same platform, we have expanded our footprint beyond DNA synthesis to manufacture synthetic RNA as well as antibody proteins to disrupt and innovate within larger market opportunities, in addition to discovery partnerships for biologic drugs and developing completely new applications for synthetic DNA, such as digital data storage.
We sell our products to a global customer base of approximately 3,562 customers across a broad range of industries.
MORE FINANCIAL SIGNALS
CRMHIGHSalesforce significantly increased debt by 71% to $14.4B while simultaneously ac...
2026-03-02
UNHHIGHUNH's operating income plummeted 41% despite 12% revenue growth, indicating seve...
2026-03-02
PFEHIGHPfizer achieved a dramatic 87.3% reduction in total debt from $31.4B to $4.0B, r...
2026-02-26
GILDHIGHGILD dramatically increased R&D spending by 81.5% to $9.1B while introducing new...
2026-02-24
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →